Jefferies Group’s vTv Therapeutics VTVT Stock Holding History

Jefferies Group’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-350	Closed	-$27K	–	2083
2020 Q1	$27K	Buy	+350	New	+$33.7K	﹤0.01%	1921

Other funds holding VTVT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jefferies Group's VTVT Position: Q2 2020 in Review

Jefferies Group sold out of vTv Therapeutics (VTVT) in Q2 2020, closing a stake of 350 shares — an estimated $27K sold.

Jefferies Group first reported a position in VTVT in Q1 2020 and held it in 1 quarter. The position peaked at $27K in Q1 2020. 39 funds tracked by Wall St. Rank hold VTVT as of Q2 2020.

Jefferies Group reported no remaining vTv Therapeutics position as of Q2 2020 after selling out during the quarter.
Jefferies Group sold 350 vTv Therapeutics shares in Q2 2020, an estimated $27K.
Jefferies Group first reported a position in vTv Therapeutics in Q1 2020 and held it in 1 quarter.
Jefferies Group's vTv Therapeutics position peaked at $27K in Q1 2020.
39 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.